VASTox prepares to commence next phase of clinical development for two neuro-disorder drug programmes
VASTox plc is preparing to commence the next set of clinical trials in its two leading neuro-disorder programmes, which target two symptoms of Parkinson's disease. This development follows positive results from initial phase I studies of the small molecule drug candidates, which show them not only to be safe but also to significantly suppress saliva and sebum production, the causes of two distressing symptoms in Parkinson's disease, sialorrhoea (drooling) and seborrhoea (greasy skin) respectively. The results from the sebum study were so pronounced, with a reduction in sebum production of 70%, that it has led VASTox to investigate this clinical candidate as a potential treatment in the multi-billion dollar acne market.
Both programmes were previously owned by DanioLabs, which was acquired by VASTox in March 2007, and the progression of these clinical programmes follows a successful period of integration into the scientific and commercial infrastructure of the enlarged Company.
In the seborrhoea programme, recruitment for the next Phase I clinical trial is underway and VASTox expects to begin this in mid 2007. In sialorrhoea, a combined Phase I/II clinical trial in patients will commence in the fourth quarter of 2007.
Other news from the department research and development
